Tempus Selected as Sequencing and Analytics Provider by the Prostate Cancer Clinical Trials Consortium for Phase II Clinical Trial
CHICAGO, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data announced today that it was selected by the Prostate Cancer …